This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Afiliações
This person is not affiliated with any business or Blue Board record at ProZ.com.
português para francês - Taxa: 0.07 - 0.09 EUR por palavra / 23 - 30 EUR por hora inglês para francês - Taxa: 0.07 - 0.09 EUR por palavra / 23 - 30 EUR por hora espanhol para francês - Taxa: 0.07 - 0.09 EUR por palavra / 23 - 30 EUR por hora francês para português - Taxa: 0.07 - 0.09 EUR por palavra / 23 - 30 EUR por hora espanhol para português - Valores: 0.07 - 0.09 EUR por palavra
inglês para português - Valores: 0.07 - 0.09 EUR por palavra
Pontos de nível PRO: 4, Perguntas respondidas: 3, Perguntas feitas: 160
Histórico de Projetos
0 Projetos inseridos
Payment methods accepted
Cheque, Transferência bancária, Ordem de pagamento
Portfolio
Amostras de tradução submetidas : 1
inglês para francês: essai clinique General field: Medicina
Texto de origem - inglês In 2001, 2 studies suggested that survival of cancer patient could be improved by EPO therapy. Head
and neck cancer patient undergoing radiotherapy had worse survival = less chance of survival or worse survival rate if they were anaemic, but, compared to historical controls, EPO therapy restored survival to that of non-anaemic patients (Glaser, 2001).
A placebo-controlled study in cancer patient on chemotherapy observed a non-significant trend of extended survival in patients receiving EPO therapy (Littlewood, 2001). A first meta-analysis carried out by the Cochrane group on 21 randomized trials confirmed that patients receiving EPO therapy had a significantly better survival than controls (Hazard ratio, HR 0.81 [0.67 to 0.99]) (Bohlius, 2005). This prompted the launch of prospective randomized trials testing the hypothesis that EPO therapy could improve survival of cancer patients. However, the first 2 published trials came out with the opposite outcome. A first trial in 351 patients with head and neck cancer undergoing curative radiotherapy and randomized to placebo or EPO therapy to target an Hb > 14 g/dL in females or > 15g/dL in males resulted in worse locoregional progression-free survival (PFS) (Henke, 2003).
Tradução - francês En 2001, deux études ont suggéré que le traitement par EPO peut améliorer la survie des patients atteints du cancer. Les patients souffrant d’un cancer de la tête et du cou qui suivent une radiothérapie avaient une moins bonne survie = moins de chance de survie ou une diminution du taux de survie s’ils étaient anémiques, mais par rapport aux contrôles historiques, le traitement par EPO ramenait ce taux au même niveau que celui des patients non anémiques (Glaser, 2001).
Un essai contrôlé contre placebo portant sur des patients atteints d’un cancer sous chimiothérapie, révèle une tendance non significative, à une survie prolongée chez les patients suivant un traitement par EPO (Littlewood, 2001). Une première méta-analyse de 21 essais aléatoires menée par le groupe Cochrane, a confirmé que la survie des patients suivant un traitement par EPO était significativement meilleure que les témoins (Risque relatif, RR 0,81 [0,67 à 0,99]) (Bohlius, 2005).
Cela a incité à réaliser des essais prospectifs randomisés destinés à tester l’hypothèse selon laquelle le traitement par EPO pourrait améliorer la survie des patients atteints du cancer. Cependant, les deux premiers essais publiés présentaient le résultat inverse. Un premier essai réalisé sur un échantillon de 351 patients souffrant d’un cancer de la tête et du cou, suivant une radiothérapie à visée curative et soumis de façon aléatoire à un traitement placebo ou par EPO, pour atteindre un taux d’hémoglobine (Hb) cible > 14 g/dl chez les femmes ou > 15 g/dl chez les hommes, a démontré une baisse de la survie sans progression locorégionale (SSP) (Henke, 2003).
More
Less
Formação educacional em tradução
Master's degree - ESTRI (Ecole Supérieure de Traduction et de Relations Internationales) Université Catholique de Lyon
Experiência
Anos de experiência em tradução: 16 Registrado no ProZ.com: Apr 2008.
inglês para francês (Université Catholique de Lyon) espanhol para francês (ESTRI, Université Catholique de Lyon) francês para português (Université Stendhal, Grenoble) francês (Université Stendhal, Grenoble) português para francês (Université Catholique de Lyon)
Associações
N/A
Software
Adobe Acrobat, Microsoft Excel, Microsoft Word, Powerpoint, Trados Studio, Wordfast
* High-quality translation that fully convey the meaning and intent of your source documents; the finished text will read as if it was originally written in French or Portuguese language
* Effective localization for French-speaking or Portuguese-speaking markets
* Precise translation of technical terms such that “nothing is lost in the translation”
* Competent translation without any guesswork
* Firm and competitive prices
* Timely delivery of services such that your deadlines are met
* Editing and proof-reading of documents
With BSTranslations you can communicate quickly and efficiently with your French-speaking or/and Portuguese-speaking clients ! Together we can overcome the language barriers...
So no need to think twice, if you have a document to be translated feel free to contact me for a free quote. BSTranslations should be your first choice !
Este associado ganhou pontos KudoZ por ajudar outros tradutores com termos de nível PRO. Clicar nos totais de pontos para ver as traduções de termos fornecidas.
Especialização